February 7, 2024

A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT:a three-arm parallel blinded randomised controlled single-centre trial.

Peter Leander, Georgios Stathis, Lucia Casal-Dujat, Karolina Boman, Ingvar Adnerhill, Jan Marsal, Olof Böök and Thomas Fork

Abstract

Background: A negative oral contrast agent (OCA) has been long sought for, to better delineate the bowel and visualise surrounding structures. Lumentin® 44 (L44) is a new OCA formulated to fill the entire small bowel. The aim of this study was to compare L44 with positive and neutral conventional OCA in abdominal computed tomography (CT).

Methods: Forty-five oncologic patients were randomised to receive either L44 or one of the two comparators (MoviPrep® or diluted Omnipaque®). Abdominal CT examinations with intravenous contrast agent were acquired according to standard protocols. The studies were read independently by two senior radiologists.

Results: The mean intraluminal Hounsfield units (HU)-values of regions-of-interest (ROIs) for each subsegment of small bowel and treatment group were -404.0 HU for L44, 166.1 HU for Omnipaque®, and 16.7 HU for MoviPrep® (L44 versus Omnipaque, p < 0.001: L44 versus MoviPrep p < 0.001; Omnipaque versus MoviPrep, p = 0.003). Adverse events, only mild, using L44 were numerically fewer than for using conventional oral contrast agents. Visualisation of abdominal structures beyond the small bowel was similar to the comparators.

Conclusions: L44 is a negative OCA with luminal radiodensity at approximately -400 HU creating a unique small bowel appearance on CT scans. The high bowel wall-to-lumen contrast may enable improved visualisation in a range of pathologic conditions. L44 showed a good safety profile and was well accepted by patients studied.

Trial registration: EudraCT (2017-002368-42) and in ClinicalTrials.gov (NCT03326518).

Keywords: Contrast media, Iohexol, Intestine (small), MoviPrep, Tomography 
(x-ray computed)

Actions

Print

Read Full Publication

References

  1. ACR–SPR (2016) 
Practice parameter for the performance of computed tomography (CT) of the abdomen and computed tomography (CT) of the pelvis. 
https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ct-abd-pel.pdf. Revised 2021
  2. Basile J, Kenny JF, Khodorkovsky B, et al (2018) 
Effects of eliminating routine use of oral contrast for computed tomography of the abdomen and pelvis: a pilot study. 
Clin Imaging 49:159–162. https://doi.org/10.1016/j.clinimag.2018.03.002
  3. Taylor MB, Bromham NR, Arnold SE (2012) 
Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. 
Br J Radiol 85:661–671. https://doi.org/10.1259/bjr/75018360
  4. Pickhardt PJ (2020) 
Positive oral contrast material for abdominal CT: current clinical indications and areas of controversy. 
AJR Am J Roentgenol 215:69–78. https://doi.org/10.2214/AJR.19.21989
  5. Fork FT, Aabakken L (2007)
Capsule enteroscopy and radiology of the small intestine. 
Eur Radiol 17:3103–3111. 10.1007/s00330-007-0718-766.
  6. Fork FT, Karlsson N, Kadhem S, Ohlsson B (2012) 
Small bowel enteroclyses with magnetic resonance imaging and computed tomography in patients with failed and uncertained passage of a patency capsule. 
BMC Med Imaging Feb 12:3. https://doi.org/10.1186/1471-2342-12-3.
  7. Megibow AJ, Babb JS, Hecht EM, et al (2006) Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology 238:87–95. https://doi.org/10.1148/radiol.2381041985

“>Scientific Advice Meetings

Already held in Q1-Q2 2022:

  • MHRA, March 2022
  • BfArM, June 2022
  • FDA, June 2022

Already held in Q1-Q2 2022:

  • MHRA, March 2022
  • BfArM, June 2022
  • FDA, June 2022